erlotinib hydrochloride has been researched along with Dermatitis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, X; Fu, H; Lin, J; Wang, Y; Zhao, Q; Zheng, Y; Zhu, C | 1 |
| Chang, GC; Chiu, CH; Hsia, TC; Jen, MH; Lin, MC; Puri, T; Shih, JY; Su, J; Su, WC; Wang, AK; Wei, YF | 1 |
| Amberg, N; Ansari, P; Boelke, E; Buhren, BA; Fischer, JW; Gerber, PA; Harder, J; Holcmann, M; Homey, B; Kislat, A; Lichtenberger, BM; Mackenzie, C; Röck, K; Schröder, JM; Schrumpf, H; Sibilia, M; Smolle, V; Wollenberg, A | 1 |
| Bhagathavula, N; Dame, MK; Dawes, SM; Elder, JT; Fu, W; Gudjonsson, JE; Johnston, A; Lambert, S; Varani, J; Ward, NL; Warner, RL | 1 |
| Cattaneo, MT; Clementi, E; Ferrario, S; Filipazzi, V; Gambaro, A; Isabella, L; Oteri, A; Piazza, E; Radice, S; Tosca, N | 1 |
| Dietrich, PY; Lübbe, J; Masouyé, I | 1 |
1 trial(s) available for erlotinib hydrochloride and Dermatitis
| Article | Year |
|---|---|
Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dermatitis; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Ramucirumab | 2023 |
5 other study(ies) available for erlotinib hydrochloride and Dermatitis
| Article | Year |
|---|---|
Xijiao Dihuang decoction relieves the erlotinib-induced dermatitis.
Topics: Animals; Chemokines; Cytokines; Dermatitis; Erlotinib Hydrochloride; Mice; Mice, Nude; Molecular Docking Simulation; Neoplasms; Quality of Life; Skin Diseases | 2023 |
Epidermal EGFR controls cutaneous host defense and prevents inflammation.
Topics: Animals; Antineoplastic Agents; Chemokines; Cytokines; Dermatitis; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Hair Follicle; Humans; Inflammation Mediators; Interleukin-1; Keratinocytes; Langerhans Cells; Lymphocytes; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Neoplasms; Quinazolines; Skin; Translational Research, Biomedical | 2013 |
Erlotinib-induced skin inflammation is IL-1 mediated in KC-Tie2 mice and human skin organ culture.
Topics: Animals; Biopsy; Dermatitis; Disease Models, Animal; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Humans; Hyperplasia; In Vitro Techniques; Interleukin-1; Mice; Mice, Transgenic; Organ Culture Techniques; Phenotype; Quinazolines; Receptor, TIE-2; Skin | 2015 |
A case of bullous dermatitis induced by erlotinib.
Topics: Adenocarcinoma; Dermatitis; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin Diseases, Vesiculobullous | 2009 |
Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva).
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Dermatitis; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kidney Neoplasms; Middle Aged; Neutrophils; Protein Kinase Inhibitors; Quinazolines; Skin | 2008 |